Eyesiu Medicines

Eyesiu Medicines is a private, pre-clinical stage biotechnology company leveraging a patented lipid nanoparticle platform for drug delivery. Its core technology enables the formulation of lipophilic compounds like PEA and cyclosporine A into stable, solvent-free nanoparticles for rapid sublingual, topical, or systemic delivery. The company has launched its first nutraceutical product (PEArlboost spray and shampoo) to generate early revenue while advancing a therapeutic pipeline targeting neurology, ophthalmology, dermatology, and pulmonology. Eyesiu is currently raising public funding through its Eyevestor platform to finance further development.

Patented solvent-free, serum-stable pegylated lipid nanoparticle (LNP) platform for encapsulating and delivering lipophilic bioactive compounds like PEA and cyclosporine A, enabling rapid sublingual, topical, or systemic delivery.

In nutraceuticals, Eyesiu competes with numerous supplement brands, differentiating on its spray delivery and PEA+B3 combination. In drug delivery, it competes with other nano-formulation and lipid particle technologies from both academia and larger biotech firms. Its specific patent estate around PEA and CsA in its LNP format provides a niche defensive position.